Indeed, small molecule activators of myosin have been previously proposed as possible drugs to counteract the effect of dilated cardiomyopathy (DCM) mutations, since these are usually associated with a decrease of the power output of the cardiac muscle [4]. Here, MYH14 is linked to familial dilated cardiomyopathy.